Randomized Controlled Crossover Trial of Ketamine in Obsessive-Compulsive Disorder: Proof-of-Concept

No abstract is available for this paper.

• Publication year

  2013

• Venue

  Neuropsychopharmacology

• Publication date

  2013-06-19

• Fields of study

  Medicine, Psychology

• Identifiers
  DOI 10.1038/npp.2013.150PMID 23783065PMCID PMC3799067
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Differential efficacy of memantine for obsessive-compulsive disorder vs. generalized anxiety disorder: an open-label trial.

  2025cited by this paper
• The Yale–Brown Obsessive Compulsive Scale

  2015cited by this paper
• A randomized trial of a low-trapping nonselective N-methyl-D-aspartate channel blocker in major depression.

  2013cited by this paper
• Rapid and longer-term antidepressant effects of repeated ketamine infusions in treatment-resistant major depression.

  2013cited by this paper
• Young Mania Rating Scale

  2013cited by this paper
• The role of eukaryotic elongation factor 2 kinase in rapid antidepressant action of ketamine.

  2013cited by this paper
• Memantine add-on in moderate to severe obsessive-compulsive disorder: randomized double-blind placebo-controlled study.

  2013cited by this paper
• Clinical experience using intranasal ketamine in the treatment of pediatric bipolar disorder/fear of harm phenotype.

  2013cited by this paper
• Replication of ketamine's antidepressant efficacy in bipolar depression: a randomized controlled add-on trial.

  2012cited by this paper
• Lack of effect of ketamine on cortical glutamate and glutamine in healthy volunteers: a proton magnetic resonance spectroscopy study

  2012cited by this paper
• N-acetylcysteine add-on treatment in refractory obsessive-compulsive disorder: a randomized, double-blind, placebo-controlled trial.

  2012cited by this paper
• A Randomized, Placebo-Controlled, Crossover Pilot Trial of the Oral Selective NR2B Antagonist MK-0657 in Patients With Treatment-Resistant Major Depressive Disorder

  2012influential reference
• Effects of ketamine in treatment-refractory obsessive-compulsive disorder.

  2012influential reference
• Ketamine effects on brain GABA and glutamate levels with 1H-MRS: relationship to ketamine-induced psychopathology

  2012cited by this paper
• The antidepressant effect of ketamine is not associated with changes in occipital amino acid neurotransmitter content as measured by [(1)H]-MRS.

  2011cited by this paper
• Glutamate abnormalities in obsessive compulsive disorder: neurobiology, pathophysiology, and treatment.

  2011cited by this paper
• Rapid resolution of obsessions after an infusion of intravenous ketamine in a patient with treatment-resistant obsessive-compulsive disorder.

  2011influential reference
• Treatment of obsessive compulsive disorder.

  2011cited by this paper
• Rapid resolution of suicidal ideation after a single infusion of an N-methyl-D-aspartate antagonist in patients with treatment-resistant major depressive disorder.

  2010cited by this paper
• mTOR-Dependent Synapse Formation Underlies the Rapid Antidepressant Effects of NMDA Antagonists

  2010cited by this paper
• A Single-Blinded Case-Control Study of Memantine in Severe Obsessive-Compulsive Disorder

  2010cited by this paper
• A screen of SLC1A1 for OCD‐related alleles

  2010cited by this paper
• Minocycline augmentation of pharmacotherapy in obsessive-compulsive disorder: an open-label trial.

  2010cited by this paper
• A randomized add-on trial of an N-methyl-D-aspartate antagonist in treatment-resistant bipolar depression.

  2010cited by this paper
• Anti-Brain Autoantibodies and Altered Excitatory Neurotransmitters in Obsessive–Compulsive Disorder

  2009cited by this paper
• Sapap3 and pathological grooming in humans: Results from the OCD collaborative genetics study

  2009cited by this paper
• Memantine Augmentation in Treatment-Resistant Obsessive-Compulsive Disorder: An Open-Label Trial

  2009cited by this paper
• Acute changes in obsessions and compulsions following moderate-intensity aerobic exercise among patients with obsessive-compulsive disorder.

  2009cited by this paper
• A family‐based association study of the glutamate transporter gene SLC1A1 in obsessive–compulsive disorder in 378 families

  2009cited by this paper
• Predicting genetic loading from symptom patterns in obsessive‐ compulsive disorder: a latent variable analysis

  2008influential reference
• Further development of YBOCS dimensions in the OCD Collaborative Genetics study: symptoms vs. categories.

  2008influential reference
• Practice guideline for the treatment of patients with obsessive-compulsive disorder.

  2007cited by this paper
• Cortico-striatal synaptic defects and OCD-like behaviours in Sapap3-mutant mice

  2007cited by this paper
• Association of the SLC1A1 glutamate transporter gene and obsessive‐compulsive disorder

  2007cited by this paper
• A randomized trial of an N-methyl-D-aspartate antagonist in treatment-resistant major depression.

  2006cited by this paper
• A systematic review: antipsychotic augmentation with treatment refractory obsessive-compulsive disorder

  2006cited by this paper
• Glutamate transporter gene SLC1A1 associated with obsessive-compulsive disorder.

  2006cited by this paper
• Treatment of obsessive-compulsive disorder by U.S. psychiatrists.

  2006cited by this paper
• A systematic review: antipsychotic augmentation with treatment refractory obsessive-compulsive disorder

  2006cited by this paper
• Association testing of the positional and functional candidate gene SLC1A1/EAAC1 in early-onset obsessive-compulsive disorder.

  2006cited by this paper
• Mechanism of action of memantine.

  2006cited by this paper
• Defining response in clinical trials for obsessive-compulsive disorder: a signal detection analysis of the Yale-Brown obsessive compulsive scale.

  2005cited by this paper
• N-acetylcysteine augmentation in serotonin reuptake inhibitor refractory obsessive-compulsive disorder

  2005cited by this paper
• Riluzole augmentation in treatment-resistant obsessive-compulsive disorder: an open-label trial.

  2005cited by this paper
• Effects of ketamine on anterior cingulate glutamate metabolism in healthy humans: a 4-T proton MRS study.

  2005cited by this paper
• Glutamatergic Dysfunction in OCD

  2005cited by this paper
• Discovering the neural basis of human social anxiety: a diagnostic and therapeutic imperative.

  2004cited by this paper
• Comparative anxiogenic, neuroendocrine, and other physiologic effects of m-chlorophenylpiperazine given intravenously or orally to healthy volunteers

  2004cited by this paper
• Reduced anterior cingulate glutamatergic concentrations in childhood OCD and major depression versus healthy controls.

  2004cited by this paper
• Association of a glutamate (NMDA) subunit receptor gene (GRIN2B) with obsessive-compulsive disorder: a preliminary study

  2004cited by this paper
• Practice guideline for the treatment of patients with schizophrenia, second edition.

  2004cited by this paper
• Early-Onset Obsessive—Compulsive Disorder

  2003cited by this paper
• Decrease in caudate glutamatergic concentrations in pediatric obsessive-compulsive disorder patients taking paroxetine.

  2000cited by this paper
• Antidepressant effects of ketamine in depressed patients.

  2000cited by this paper
• Glutamatergic drugs exacerbate symptomatic behavior in a transgenic model of comorbid Tourette's syndrome and obsessive-compulsive disorder.

  2000cited by this paper
• Pharmacotherapy of obsessive-compulsive disorder in a health maintenance organization.

  2000cited by this paper
• Patterns of remission and relapse in obsessive-compulsive disorder: a 2-year prospective study.

  1999cited by this paper
• Delayed obsessive-compulsive disorder symptom exacerbation after a single dose of a serotonin antagonist in fluoxetine-treated but not untreated patients

  1998cited by this paper
• Measurement of Dissociative States with the Clinician-Administered Dissociative States Scale (CADSS)

  1998cited by this paper
• Activation of Glutamatergic Neurotransmission by Ketamine: A Novel Step in the Pathway from NMDA Receptor Blockade to Dopaminergic and Cognitive Disruptions Associated with the Prefrontal Cortex

  1997cited by this paper
• Structured Clinical Interview for DSM-IV Axis I Disorders

  1997cited by this paper
• The Yale-Brown Obsessive-Compulsive Scale: measures of internal consistency.

  1994cited by this paper
• Some conceptual and statistical issues in analysis of longitudinal psychiatric data. Application to the NIMH treatment of Depression Collaborative Research Program dataset.

  1993cited by this paper
• The Yale-Brown Obsessive Compulsive Scale: I. Development, Use, and Reliability

  1989cited by this paper
• The Yale-Brown Obsessive Compulsive Scale. II. Validity.

  1989cited by this paper
• The Yale-Brown Obsessive Compulsive Scale. I. Development, use, and reliability.

  1989cited by this paper
• A Rating Scale for Mania: Reliability, Validity and Sensitivity

  1978cited by this paper
• The Brief Psychiatric Rating Scale

  1962cited by this paper
• A RATING SCALE FOR DEPRESSION

  1960influential reference

• Comments on "Ketamine's double-edged sword: Therapeutic benefits and adverse events in adolescent treatment-resistant obsessive compulsive disorder (OCD)-A case series".

  2026cites this paper
• Clinical practice guidelines for obsessive-compulsive disorder: 2025 update

  2026influential citation
• Ketamine as a Mental Health Treatment.

  2026cites this paper
• Marked Improvement in Treatment-Intolerant Obsessive-Compulsive Disorder in an Adolescent Using a Glutamatergic Regimen With Dextromethorphan, Piracetam, and Goldenseal Root.

  2026cites this paper
• Canadian Network for Mood and Anxiety Treatments (CANMAT) and International College of Obsessive-Compulsive Spectrum Disorders (ICOCS) 2025 International Guidelines for the Management of Patients with Obsessive-Compulsive Disorder

  2026cites this paper
• Management of obsessive-compulsive disorder in adults

  2026cites this paper
• Hope for Neurotic Disorders: A Summary of New Zealand Research on the Development of Biomarkers and Novel Treatments.

  2026cites this paper
• Effects of ketamine and esketamine on death, suicidal behaviour, and suicidal ideation in psychiatric disorders: A systematic review and meta-analysis

  2025cites this paper
• Ketamine-induced static and dynamic functional connectivity changes are modulated by opioid receptors and biological sex in rats

  2025cites this paper
• Ketamine Treatment for Pediatric Refractory Obsessive: Five Open Label Cases

  2025cites this paper
• Royal Australian and New Zealand College of Psychiatrists professional practice guidelines for the use of ketamine in psychiatric practice

  2025cites this paper
• Ketamine’s double-edged sword: Therapeutic benefits and adverse events in adolescent treatment-resistant OCD - A case series

  2025cites this paper
• Agonism at mGluR2 receptors reduces dysfunctional checking on a rodent analogue of compulsive-like checking in obsessive compulsive disorder

  2025cites this paper
• Ketamine and Esketamine in Psychiatry: A Comparative Review Emphasizing Neuroplasticity and Clinical Applications

  2025cites this paper
• L-type voltage-dependent calcium channels in the ventromedial orbitofrontal and prefrontal cortices mediate the inhibitory effects of (S)-ketamine but not (R)-ketamine on marble burying in male mice.

  2025cites this paper
• The Effects of Psychotherapy on Single and Repeated Ketamine Infusion(s) Therapy for Treatment-Resistant Depression: The Convergence of Molecular and Psychological Treatment

  2025cites this paper
• Psilocybin and Obsessive-Compulsive Disorder: Exploring New Therapeutic Horizons

  2025cites this paper
• Ketamine in clinical practice: transitioning from anesthetic agent to psychiatric therapeutic

  2025cites this paper
• Subanesthetic Ketamine Ameliorates Activity‐Based Anorexia of Adult Mice

  2025cites this paper
• Ketogenic Diet as a Nutritional Metabolic Intervention for Obsessive–Compulsive Disorder: A Narrative Review

  2024cites this paper
• Striking Long Term Beneficial Effects of Single Dose Psilocybin and Psychedelic Mushroom Extract in the SAPAP3 Rodent Model of OCD-Like Excessive Self-Grooming

  2024cites this paper
• Ketamine for the Treatment of Psychiatric Disorders: A Systematic Review and Meta-Analysis

  2024cites this paper
• Glutamate dynamics and BOLD response during OCD symptom provocation in the lateral occipital cortex: A 7 Tesla fMRI-fMRS study.

  2024cites this paper
• Ketamine Infusion in a Resistant Obsessive-Compulsive Disorder Patient in Bangladesh with Severe Suicidal Ideation: A Case Report

  2024influential citation
• Hereditary Patterns and Genetic Associations in Obsessive-Compulsive Disorder (OCD): Neuropsychiatric Insights, Genetic Influences, and Treatment Perspectives

  2024cites this paper
• Acute Dissociation and Ketamine’s Antidepressant and Anti-Suicidal Ideation Effects in a Midazolam-Controlled Trial

  2024cites this paper
• An evaluation of treatment response and remission definitions in adult obsessive-compulsive disorder: A systematic review and individual-patient data meta-analysis.

  2024cites this paper
• A novel framework for ketamine-assisted couple therapy

  2024cites this paper
• Ketamine for treatment-resistant obsessive-compulsive disorder: Double-blind active-controlled crossover study

  2024cites this paper
• Psilocybin in pharmacotherapy of obsessive-compulsive disorder

  2024cites this paper
• Esketamine Augmentation in Treatment-Resistant Obsessive-Compulsive Disorder: A Retrospective Chart Review

  2024cites this paper
• New horizons for obsessive-compulsive disorder drug discovery: is targeting glutamate receptors the answer?

  2024cites this paper
• A molecularly defined orbitofrontal cortical neuron population controls compulsive-like behavior, but not inflexible choice or habit.

  2024cites this paper
• Repurposing General Anesthetic Drugs to Treat Depression: A New Frontier for Anesthesiologists in Neuropsychiatric Care.

  2024cites this paper
• Psychedelics, epilepsy, and seizures: a review

  2024cites this paper
• A Comprehensive Review on Obsessive-Compulsive Disorder: An Update

  2024cites this paper
• Repeated oral esketamine in patients with treatment resistant depression and comorbid posttraumatic stress disorder

  2023cites this paper
• [Combination of ketamine and esketamine with Exposure and Response Prevention (ERP) therapy for Obsessive-Compulsive Disorder].

  2023cites this paper
• Mechanisms of pathogenesis and environmental moderators in preclinical models of compulsive-like behaviours.

  2023cites this paper
• Psychedelic therapies reconsidered: compounds, clinical indications, and cautious optimism

  2023cites this paper
• Obsesif Kompulsif ve İlişkili Bozuklukların Tedavisinde Glutamaterjik Modülatörlerin Rolü

  2023cites this paper
• A systematic review of the incidence of medical serious adverse events in sub-anesthetic ketamine treatment of psychiatric disorders.

  2023cites this paper
• Considerations for the treatment of obsessive-compulsive disorder in patients who have comorbid major depression

  2023cites this paper
• Ketamine in neuropsychiatric disorders: an update

  2023cites this paper
• Targeting inflammatory signaling in obsessive compulsive disorder: a promising approach

  2023influential citation
• Regulating Ketamine Use in Psychiatry

  2023cites this paper
• Clinical case report: considerable improvement of severe and difficult-to-treat obsessive-compulsive disorder with comorbid depression under treatment with esketamine and concomitant psychotherapy

  2023cites this paper
• Acute administration of the NMDA receptor antagonists ketamine and MK-801 reveals dysregulation of glutamatergic signalling and sensorimotor gating in the Sapap3 knockout mouse model of compulsive-like behaviour.

  2023cites this paper
• Psychedelics in the treatment of eating disorders: Rationale and potential mechanisms.

  2023cites this paper
• The Emerging Role of Ketamine in Acute Postoperative Pain Management

  2023cites this paper
• Assessment of the anxiolytic, antidepressant, and antioxidant potential of Parquetina nigrescens (Afzel.) Bullock in Wistar rats.

  2023cites this paper
• Pharmacotherapy: Ketamine and Esketamine.

  2023cites this paper
• L‐theanine combination therapy with fluvoxamine in moderate‐to‐severe obsessive–compulsive disorder: A placebo‐controlled, double‐blind, randomized trial

  2023cites this paper
• Clinical Effectiveness of N-Methyl-D-Aspartate (NMDA) Receptor Antagonists in Adult Obsessive-Compulsive Disorder (OCD) Treatment: A Systematic Review

  2023cites this paper
• Anxiolytic-like effects of an mGluR 5 antagonist and a mGluR 2/3 agonist, and antidepressant-like effects of an mGluR 7 agonist in the chick social separation stress test, a dual-drug screening model of treatment-resistant depression.

  2023cites this paper
• Safety, tolerability, and clinical and neural effects of single-dose psilocybin in obsessive–compulsive disorder: protocol for a randomized, double-blind, placebo-controlled, non-crossover trial

  2023cites this paper
• Accelerated deep transcranial magnetic stimulation using iTBS protocol for refractory obsessive-compulsive disorder.

  2023cites this paper
• Brazilian Research Consortium on Obsessive-Compulsive Spectrum Disorders guidelines for the treatment of adult obsessive-compulsive disorder. Part I: pharmacological treatment

  2023cites this paper
• The metabotropic glutamate receptor 5 as a biomarker for psychiatric disorders.

  2023cites this paper
• New and emerging approaches to treat psychiatric disorders

  2023cites this paper
• A pilot randomized controlled trial of ketamine in Borderline Personality Disorder

  2023cites this paper
• The Pharmacological Treatment of Obsessive-Compulsive Disorder.

  2023cites this paper
• Novel Ketamine and Zinc Treatment for Anorexia Nervosa and the Potential Beneficial Interactions With the Gut Microbiome.

  2023cites this paper
• Role of the mesolimbic dopamine pathway in the antidepressant effects of ketamine.

  2022cites this paper
• A transdiagnostic systematic review and meta-analysis of ketamine’s anxiolytic effects

  2022influential citation
• S-ketamine exerts sex- and dose-dependent anti-compulsive-like effect as monotherapy or in augmentation to fluoxetine.

  2022cites this paper
• Right Frontal Theta: Is It a Response Biomarker for Ketamine’s Therapeutic Action in Anxiety Disorders?

  2022cites this paper
• Ketamine selectively changes outcome valuation in a biased matching pennies task

  2022cites this paper
• An Innovative Approach to Extending the Antidepressant Effects of Intravenous Ketamine in Major Depression.

  2022cites this paper
• Ketamine treatment for depression: a review

  2022cites this paper
• Neurocognitive effects of repeated ketamine infusions in comorbid posttraumatic stress disorder and major depressive disorder.

  2022cites this paper
• Acute (R,S)-Ketamine Administration Induces Sex-Specific Behavioral Effects in Adolescent but Not Aged Mice

  2022cites this paper
• Stress, mental disorder and ketamine as a novel, rapid acting treatment.

  2022cites this paper
• Treatment-resistant OCD: Pharmacotherapies in adults.

  2022cites this paper
• Prophylactic (R,S)-Ketamine Is Effective Against Stress-Induced Behaviors in Adolescent but Not Aged Mice

  2022cites this paper
• Ketamine in the Treatment of Obsessive-Compulsive Disorder: A Systematic Review

  2022cites this paper
• A case series of group-based ketamine-assisted psychotherapy for patients in residential treatment for eating disorders with comorbid depression and anxiety disorders

  2022cites this paper
• Clinical use of ketamine in psychiatric disorders

  2022cites this paper
• Non-parenteral Ketamine for Depression: A Practical Discussion on Addiction Potential and Recommendations for Judicious Prescribing

  2022cites this paper
• Serum Levels of Brain-Derived Neurotrophic Factor in Patients with Obsessive-Compulsive Disorder in a Japanese Population

  2021cites this paper
• Structure, Function, and Pharmacology of Glutamate Receptor Ion Channels

  2021cites this paper
• Pharmacotherapeutic Strategies and New Targets in OCD.

  2021cites this paper
• Meta-Analysis: Hemodynamic Responses to Sub-anesthetic Doses of Ketamine in Patients With Psychiatric Disorders

  2021cites this paper
• Ketamin und andere N-Methyl-D-Aspartat-Rezeptor-Modulatoren zur Behandlung der Depression

  2021cites this paper
• Novel Glutamatergic Modulators for the Treatment of Mood Disorders: Current Status

  2021cites this paper
• Obsessive Compulsive Disorder: Neurobiology and Treatment

  2021cites this paper
• Specialty knowledge and competency standards for pharmacotherapy for adult obsessive-compulsive disorder.

  2021cites this paper
• Obsessive-Compulsive Disorder Driven by Aspects of Ritual Addiction: A Case Report and Review of Literature.

  2021cites this paper
• Hydroxynorketamines: Pharmacology and Potential Therapeutic Applications

  2021cites this paper
• Clinical trials for rapid changes in suicidal ideation: Lessons from ketamine.

  2021influential citation
• Synthesizing the Evidence for Ketamine and Esketamine in Treatment-Resistant Depression: An International Expert Opinion on the Available Evidence and Implementation.

  2021cites this paper
• Human Laboratory Models of Cannabis Use: Applications for Clinical and Translational Psychiatry Research

  2021cites this paper
• Systematic review and meta-analysis of randomized controlled trials of ketamine in the treatment of refractory anxiety spectrum disorders

  2021cites this paper
• Ketamine increases activity of a fronto-striatal projection that regulates compulsive behavior in SAPAP3 knockout mice

  2021cites this paper
• Oral S-ketamine effective after deep brain stimulation in severe treatment-resistant depression and extensive comorbidities

  2021cites this paper
• Depression and Anxiety Disorders

  2021cites this paper
• Ketamine for PTSD: Well, Isn't That Special.

  2021cites this paper
• Developing an IV Ketamine Clinic for Treatment-Resistant Depression: a Primer.

  2021cites this paper
• The use of esketamine in comorbid treatment resistant depression and obsessive compulsive disorder following extensive pharmacogenomic testing: a case report

  2021cites this paper
• Antiglutamatergic agents for obsessive-compulsive disorder: Where are we now and what are possible future prospects?

  2021cites this paper